Evidence map›Paper›PMID 39157907›Full record

ArticleAllergy2024

Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA-1273 COVID-19 vaccine.

Manon Scholaert, Mathias Peries, Emilie Braun, Jeremy Martin, Nadine Serhan, Alexia Loste, Audrey Bruner, Lilian Basso, Benoît Chaput, Eric Merle and 3 more

Abstract read
In one paragraph

Article in Allergy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Manon ScholaertToulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.
Mathias PeriesGenoskin SAS, Toulouse, France.
Emilie BraunGenoskin SAS, Toulouse, France.
Jeremy MartinToulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.
Nadine SerhanToulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.
Alexia LosteToulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.
Audrey BrunerToulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.
Lilian BassoToulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.ORCID 0000-0002-2816-1557
Benoît ChaputDepartment of Plastic, Reconstructive and Aesthetic Surgery, Rangueil Hospital, CHU Toulouse, Toulouse, France.
Eric MerleGenoskin Inc, Salem, Massachusetts, USA.
Pascal DescarguesGenoskin Inc, Salem, Massachusetts, USA.
Emeline PagèsGenoskin SAS, Toulouse, France.
Nicolas GaudenzioToulouse Institute for Infectious and Inflammatory Diseases (Infinity) INSERM UMR1291-CNRS UMR5051, University Toulouse III, Toulouse, France.ORCID 0000-0002-5648-509X

Funding

Agence Nationale de la RechercheEuropean Research CouncilGenoskin
6 · The paper itself

Abstract

backgroundThe field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials.

methodsHere we introduce a new flexible solution designed for the comprehensive monitoring of the natural human skin ecosystem's response to immunogenic drugs over time. Based on unique bioengineering to preserve surgical resections in a long survival state, it allows for the first time a comprehensive analysis of resident immune cells response at both organ and single-cell levels.

resultsUpon injection of the mRNA-1273 COVID-19 vaccine, we characterized precise sequential molecular events triggered upon detection of the exogenous substance. The vaccine consistently targets DC/macrophages and mast cells, regardless of the administration route, while promoting specific cell-cell communications in surrounding immune cell subsets.

conclusionGiven its direct translational relevance, this approach provides a multiscale vision of genuine human tissue immunity that could pave the way toward the development of new vaccination and drug development strategies.

Indexed as

2019-nCoV Vaccine mRNA-1273COVID-19SARS-CoV-2SkinCOVID-19 VaccinesDendritic CellsHumansMacrophagesMast Cells2019-nCoV Vaccine mRNA-1273COVID-19 Vaccineshuman skin modulesimmune responsemRNA vaccine trackingmultiplexed imagingsingle‐cell RNA‐Seq

Identifiers

PMID39157907
PMCPMC11657073

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.